Answers are grounded in this paper and cite their sources.
Major depressive disorder (MDD) is a pressing mental health problem globally. Under the contemporary era, significant progress has been achieved in understanding the pathogenic mechanisms of MDD. Pharmacotherapy, especially SSRIs, works as the most frequent option in MDD treatment. To identify a molecule with prompt effectiveness and minimal adverse effects is the overarching objective, but the mechanisms underlying the therapeutic effects in the MDD treatment remain nuanced and are not completely revealed. This literature review describes mechanisms, clinical trials conducted, therapeutic benefits along with adverse effects discovered of several key antidepressants, and aims to provide insights into the future antidepressant discovery, development and application. SSRIs together with SNRIs have acute effects on the monoaminergic system, but their strength is subject to limitations imposed by delayed or inadequate therapeutic efficacy, suboptimal remission outcomes, and adverse reactions. Consequently, novel and more efficacious antidepressant therapeutic agents are identified and developed. The review covers the recent clinical findings of a few promising antidepressants, and found that rapid-acting, oral administration, and substantial benefits in both remission and response are optimal features for antidepressants. Taken together, further explorations into both the pharmacological and pathophysiological mechanisms remain necessary. Future studies regarding the assessments of prolonged therapeutic benefits, safety profiles, recognitions of novel biomarkers among MDD patients especially with substance use disorders and/or treatment-resistant depression are also essential.
No takes yet. Share an insight, caveat, or question.
Huimin Song (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: